FDA Approves ETICOVO™ (etanercept-ykro), Samsung Bioepis' Second Anti-TNF Medicine in the United States - Yahoo Finance

FDA Approves ETICOVO™ (etanercept-ykro), Samsung Bioepis' Second Anti-TNF Medicine in the United States  Yahoo Finance

Samsung Bioepis expands autoimmune portfolio in the United States with FDA approval of ETICOVO™ , a biosimilar referencing ENBREL®i .